万泰生物涨2.00%，成交额7019.30万元，主力资金净流入267.99万元

Core Viewpoint - Wante Bio's stock price has shown a slight increase of 2.00% recently, but the company has experienced a significant decline in revenue and profit year-on-year, indicating potential challenges ahead [1][2]. Group 1: Stock Performance - As of January 5, Wante Bio's stock price reached 45.84 CNY per share, with a market capitalization of 57.96 billion CNY [1]. - The stock has seen a 2.00% increase year-to-date, but has declined by 2.11% over the last five trading days, 1.46% over the last twenty days, and 21.12% over the last sixty days [1]. Group 2: Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion CNY, a decrease of 23.09% year-on-year [2]. - The company recorded a net profit of -173 million CNY, representing a significant decline of 165.04% compared to the previous year [2]. Group 3: Shareholder Information - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.60% to 30,124 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which reduced its holdings by 9.8553 million shares, and new shareholder招商国证生物医药指数A, holding 4.9609 million shares [3].